Replimune Group (NASDAQ:REPL) Sees Strong Trading Volume

Replimune Group Inc (NASDAQ:REPL) saw strong trading volume on Thursday . 1,667,424 shares changed hands during trading, an increase of 2,392% from the previous session’s volume of 66,912 shares.The stock last traded at $13.64 and had previously closed at $13.61.

A number of equities analysts have weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and set a $28.00 price target on shares of Replimune Group in a research note on Thursday, October 24th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 price target on shares of Replimune Group in a research note on Monday, September 30th. ValuEngine raised shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Roth Capital increased their price target on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Zacks Investment Research downgraded shares of Replimune Group from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $25.17.

The company has a market cap of $544.97 million, a PE ratio of -10.26 and a beta of 3.30. The stock’s 50 day simple moving average is $14.54 and its two-hundred day simple moving average is $13.45.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.01). On average, equities research analysts predict that Replimune Group Inc will post -1.39 earnings per share for the current fiscal year.

In other news, CEO Robert Coffin sold 48,500 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $16.92, for a total value of $820,620.00. Also, COO Colin Love sold 11,250 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $17.05, for a total transaction of $191,812.50. In the last ninety days, insiders have sold 200,000 shares of company stock worth $3,395,500. 63.18% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Emerald Mutual Fund Advisers Trust increased its position in shares of Replimune Group by 0.5% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock worth $10,435,000 after acquiring an additional 3,650 shares in the last quarter. Citadel Advisors LLC increased its position in shares of Replimune Group by 5.7% in the second quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock worth $2,731,000 after acquiring an additional 10,009 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Replimune Group by 211.3% in the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock worth $338,000 after acquiring an additional 15,672 shares in the last quarter. BlackRock Inc. increased its position in shares of Replimune Group by 8.2% in the second quarter. BlackRock Inc. now owns 1,015,225 shares of the company’s stock worth $14,883,000 after acquiring an additional 76,540 shares in the last quarter. Finally, Emerald Advisers LLC increased its position in shares of Replimune Group by 5.2% in the third quarter. Emerald Advisers LLC now owns 728,890 shares of the company’s stock worth $10,132,000 after acquiring an additional 35,712 shares in the last quarter. 60.92% of the stock is owned by institutional investors.

About Replimune Group (NASDAQ:REPL)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: Should you buy a closed-end mutual fund?

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.